UNSPSC 51292927: Opipramol hydrochloride

This classification denotes an anxiolytic with the molecular formula C23H29N3O.2ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier B49OBI656M, chemically known as 5-(gamma-(beta-hydroxyethylpiperazino)propyl)-5h-dibenzo(b,f)azepine dihydrochloride but more generally known as opipramol hydrochloride, which bears US NIH Compound Identifier 71587. European Medicines Agency schedules Opipramol hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03520MIG.

UNSPSC 51292927 Opipramol hydrochloride is a Commodity code for a specific antidepressant pharmaceutical, but the recent state and local solicitations tagged under it bear no material relationship to this product. The code shows little relevant recent activity; instead, opportunities posted under this number address naloxone procurement, direct-to-manufacturer prescription programs, and multi-source generic pharmaceuticals and OTC products — none of which involve opipramol hydrochloride or its specific therapeutic class. The mismatch suggests either a classification error in how the opportunities were tagged or that the code is not actively used to describe the pharmaceutical work state and local agencies are actually buying today.

The three most recent opportunities span diverse issuing bodies and procurement approaches. Seminole County, Florida issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through an IFB with response due July 26, 2023 — a date that appears to be a data error. The Texas Health and Human Services Commission released RFI HHS0017013 on April 3, 2026, to gather vendor capabilities on a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program with no formal award timeline. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, seeking generic multi-source pharmaceuticals and OTC products for statewide and participating jurisdictions including Oregon, with proposals due March 26, 2026. Because none of these opportunities actually procure opipramol hydrochloride, the code does not present a current market signal for this specific product.